Abstract | BACKGROUND: OBJECTIVE: To assess therapeutic options for patients with psoriasis and concurrent IBD. METHODS: A systematic literature search was performed for clinical studies of biologic and systemic psoriasis medications in psoriasis, psoriatic arthritis, ulcerative colitis, and Crohn's disease, for the period from January 1, 1947, to February 14, 2017. Randomized, controlled, double-blinded studies were selected if available. If not, the next highest level of available evidence was selected. RESULTS: LIMITATIONS: There are no known clinical trials of treatment specifically for concurrent psoriasis and IBD. CONCLUSIONS:
|
Authors | Scott M Whitlock, Clinton W Enos, April W Armstrong, Alice Gottlieb, Richard G Langley, Mark Lebwohl, Joseph F Merola, Caitriona Ryan, Michael P Siegel, Jeffrey M Weinberg, Jashin J Wu, Abby S Van Voorhees |
Journal | Journal of the American Academy of Dermatology
(J Am Acad Dermatol)
Vol. 78
Issue 2
Pg. 383-394
(02 2018)
ISSN: 1097-6787 [Electronic] United States |
PMID | 29332708
(Publication Type: Journal Article, Review)
|
Copyright | Copyright © 2017 American Academy of Dermatology, Inc. Published by Elsevier Inc. All rights reserved. |
Chemical References |
- Antibodies, Monoclonal
- Antibodies, Monoclonal, Humanized
- Dermatologic Agents
- Gastrointestinal Agents
- guselkumab
- Thalidomide
- brodalumab
- Cyclosporine
- golimumab
- Infliximab
- ixekizumab
- secukinumab
- Ustekinumab
- Adalimumab
- Acitretin
- Etanercept
- Certolizumab Pegol
- apremilast
|
Topics |
- Acitretin
(therapeutic use)
- Adalimumab
(therapeutic use)
- Antibodies, Monoclonal
(therapeutic use)
- Antibodies, Monoclonal, Humanized
(therapeutic use)
- Certolizumab Pegol
(therapeutic use)
- Cyclosporine
(therapeutic use)
- Dermatologic Agents
(therapeutic use)
- Etanercept
(therapeutic use)
- Gastrointestinal Agents
(therapeutic use)
- Humans
- Inflammatory Bowel Diseases
(complications, drug therapy)
- Infliximab
(therapeutic use)
- Psoriasis
(complications, therapy)
- Thalidomide
(analogs & derivatives, therapeutic use)
- Ustekinumab
(therapeutic use)
|